Viridian Therapeutics share price today

Viridian Therapeutics, Inc.'s share price was $29.05 at the close on 4 November 2026. It has been stalling near its high for 3 weeks. That is 34.1% above its average price over the last 200 trading days.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Viridian Therapeutics, Inc. is in stage 3. The phase helps read everything below.

In the last 52 weeks it traded between $13 and $33, and at that close it sat 79% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 4 weeks in a row.

Over the last 9.7 years the share price moved −84% while the S&P 500 moved +226%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Viridian Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Viridian Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Viridian Therapeutics, Inc. posted a net loss of ₹0.1 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.3 B. That loss is 39,727.1% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier lost ₹0.1 B. 12 of the last 12 reported quarters were loss-making.

Read this profit with care: at −₹0.1 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −44,460.6% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings.

This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted.

Viridian Therapeutics, Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter, +278.7% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 4 years it has grown 121.1% a year on average. The last full year, FY25, came in at ₹0.1 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹0.1 B.

Recent pace: the last four quarters grew +152.6% on average, against 121.1% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +23,220.3%, against +1,471.5% a year over the last 8 quarters (accelerating).

This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted.

Viridian Therapeutics, Inc. has almost no sales yet: FY25 revenue was ₹0.1 B. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow.

Viridian Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.3 B of cash, against −₹0.3 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.3 B: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures.

This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted.

Viridian Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Spending on assets: ₹0.0 B over the last 3 years.

In short: almost nothing is being spent on new assets, so the cash goes on running the business.

This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted.

Viridian Therapeutics, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Viridian Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Viridian Therapeutics, Inc. earned a ROE of −39% in FY25. That is up from a low of −42% in FY21. Its return on capital used (ROIC) is left out: on sales this small it reads −43%, a number that says nothing useful about the business.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Viridian Therapeutics, Inc. has total debt of ₹0.2 B against shareholder equity of ₹0.7 B as of Jun 2026, so its debt is 0.37× its equity. Year by year, that ratio went from 0.00 in FY21 to 0.07 in FY25. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted.

17.9% of Viridian Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 8.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Viridian Therapeutics, Inc., the Z-score is 0.93. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 0.93 is inside the danger zone, so the balance sheet is a real risk.

There is no score against its industry: Viridian Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology.

The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown.

No sector comparison is shown here, not among the largest members shown in this industry comparison.

Viridian Therapeutics is the 58th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: ACADIA Pharmaceuticals Inc., Tarsus Pharmaceuticals, Inc. and Denali Therapeutics Inc. Just below it: Telix Pharmaceuticals, IDEAYA Biosciences, Inc. and Zai Lab.

Biotechnology companies close in size

55. ACADIA Pharmaceuticals Inc. $3.7 billion
56. Tarsus Pharmaceuticals, Inc. $3.4 billion
57. Denali Therapeutics Inc. $3.4 billion
58. Viridian Therapeutics, Inc. $3.3 billion
59. Telix Pharmaceuticals Limited $3.2 billion
60. IDEAYA Biosciences, Inc. $3.1 billion
61. Zai Lab Limited $2.8 billion

All 211 Biotechnology companies, largest first

Companies close in size in other industries

1664. Seaboard Corporation $3.3 billion · Conglomerates
1665. Kenon Holdings Ltd. $3.3 billion · Utilities - Independent Power Producers
1666. Viridian Therapeutics, Inc. $3.3 billion
1667. Stride, Inc. $3.3 billion · Education & Training Services
1668. Artisan Partners Asset Management Inc. $3.3 billion · Asset Management

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.